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Introduction: Inflammation plays a crucial role in tissue regeneration, wound healing, and the success of
tissue-engineered constructs. The aim of this study was to investigate the influence of human umbilical vein
endothelial cells (ECs) on leukocyte transmigration when co-cultured with primary human bone marrow-derived
multipotent stromal cells (MSCs).
Methods: MSCs with and without ECs were cultured in poly (L-lactide-co-1, 5-dioxepan-2-one) (poly (LLA-co-DXO))
scaffolds for 1 week in vitro in a bioreactor system, after which they were implanted subcutaneously in
non-obese diabetic/severe combined immunodeficient mice. After 1 and 3 weeks, scaffolds were retrieved, and
the mRNA expression of interleukin 1-beta (IL-1β), IL-6, IL-10, hypoxia-inducible factor 1-alpha (HIF-1α), HIF-1β,
and mammalian target of rapamycin was examined by real-time reverse transcription-polymerase chain reaction.
Furthermore, immunofluorescent staining was performed for IL-1β, IL-6, neutrophils, and CD11b. In addition,
Western blotting was done for IL-1β and IL-6. Leukocyte transmigration genes and genes in Toll-like receptor
pathways, expressed by MSCs cultured in vitro with or without ECs, were further investigated with a
microarray dataset.
Results: In vitro, genes involved in leukocyte transmigration and Toll-like receptor pathways were clearly
influenced by the addition of ECs. Platelet/endothelial cell adhesion molecule-1 (PECAM-1) and cadherin-5 (CDH5),
both genes involved in leukocyte transmigration, were expressed significantly higher in the MSC/EC group.
In vivo, the MSC/EC group showed higher mRNA expression of hypoxia-inducible factors HIF-1α and HIF-1β. The
mRNA expression of anti-inflammatory cytokine IL-10 showed no significant difference, whereas the mRNA and
protein expression of pro-inflammatory cytokines IL-1β and IL-6 were lower in the MSC/EC group. The quantitative
analysis of immunofluorescent staining revealed a significant difference in the number of neutrophils migrating
into constructs, with the highest density found in the MSC/EC group. The number of macrophages positive for
IL-6 and CD11b was significantly reduced in the MSC/EC group.
Conclusions: The recruitment of leukocytes into tissue-engineered constructs with MSCs is strongly influenced by
the addition of ECs via activation of leukocyte transmigration and Toll-like receptor pathways.* Correspondence: torbjorn.pedersen@iko.uib.no
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Re-establishing the function of lost tissues is the ultim-
ate goal of tissue engineering. The process of regenerat-
ing complex tissues is, however, not only dependent on
progenitor cells differentiating to specialized parenchy-
mal cells. Development of an adequate blood supply is re-
quired to ensure survival of implanted cells as well as
development and maintenance of the tissue. Under defined
mechanochemical culture conditions, primary human bone
marrow-derived multipotent stromal cells (MSCs) can dif-
ferentiate into osteoblasts, chondrocytes, adipocytes, myo-
cytes, and neuronal-like cells [1,2]. The differentiation of
MSCs into endothelial cells (ECs) has been shown [3] but is
controversial [4]. Pre-vascularization through co-seeding of
MSCs and ECs has therefore been performed to generate
tissue-engineered constructs with an intrinsic vasculature
upon implantation in vivo [5-8].
The influence of ECs on osteogenic differentiation of
MSCs has been extensively studied, identifying ECs as an
important regulator of MSC commitment to the osteo-
genic lineage [9-11]. Microarray data have shown that ECs
modulate the gene expression profile of MSCs, in parti-
cular through the transforming growth factor-beta path-
way [12]. In addition, recent work has identified MSCs
as appropriate perivascular cells in tissue-engineered con-
structs containing both ECs and MSCs [13]. The commu-
nication between the two cell types is a combination of
juxtacrine and paracrine signaling. Vascular assembly has
an obvious requirement for direct contact communication,
with MSCs regulating EC proliferation, vessel diameter,
and maturation of the developing vasculature [6,7]. How-
ever, the release of bioactive molecules (cytokines, che-
mokines, and growth factors) is a significant part of the
cellular cross-talk and alters the signal delivered to sur-
rounding tissues after in vivo implantation, thus playing a
vital role in the success of the constructs.
Surgical procedures induce acute inflammation that
triggers wound healing, repair, and regeneration [14,15].
Also, implantation of cells and biomaterials is likely to re-
sult in a combination of acute and chronic inflammatory
stimulation to surrounding tissues. In addition, MSCs have
been shown to interact with immune cells and modulate
their functional activities through the release of anti-
inflammatory cytokines [16,17].
In some cases, fibrosis hinders vascularization, which
leads to a necrotic core of implanted tissue-engineered con-
structs. Inflammation and angiogenesis are co-dependent
processes in certain pathological processes and in wound
healing [18]. A certain level of inflammation is therefore
favorable for vascular ingrowth and degradation of the
scaffold material and subsequently in achieving the max-
imal level of regeneration and implant success [19,20].
The vascular endothelium facilitates leukocyte trans-
migration upon chemotactic signals from damaged orhypoxic tissues. The effects of including a vascular endo-
thelium in a tissue-engineered construct on migration of
leukocytes are, however, not well described. We studied
the transmigration of leukocytes involved in acute and
chronic inflammation into constructs with or without an
intrinsic vasculature and the molecular mechanisms
behind its modulation.
Materials and methods
In vitro cultivation of cells
Primary human bone marrow-derived MSCs were pur-
chased from StemCell Technologies (Vancouver, BC,
Canada). Purity of the cells was confirmed by flow cy-
tometry, which showed that more than 90% of the cells
expressed CD29, CD44, CD105, and CD166 and less
than 1% expressed CD14, CD34, and CD45. The MSCs
were cultured in MesenCult complete medium (StemCell
Technologies) in accordance with the instructions of
the manufacturer.
Human umbilical vein ECs were purchased from
Lonza (Clonetics®, Walkersville, MD, USA). ECs were
expanded in EC growth medium (EGM®) (Lonza) con-
taining 500 mL EC basal medium and supplements: fetal
bovine serum 10 mL, bovine brain extract [21] 2 mL,
human endothelial growth factor 0.5 mL, hydrocortisone
0.5 mL, and GA-1000 0.5 mL. Cells no older than pas-
sage five were used, and all cells were cultured at 37°C
and 5% CO2.
Production of scaffolds
Poly(L-lactide-co-1,5dioxepan-2-one) [poly(LLA-co-DXO)]
scaffolds were prepared as previously described [22,23].
Briefly, porous scaffolds (pore sizes of 90 to 500 μm)
were produced from co-polymer poly(LLA-co-DXO)
by a solvent-casting particulate-leaching method. The
sterilization of scaffolds was carried out in a pulsed
electron accelerator operating at 6.5 MeV (Mikrotron,
Acceleratorteknik, The Royal Institute of Technology,
Stockholm, Sweden) with a radiation dose of 2.5 Megarad
(Mrad) in an inert atmosphere.
Preparation for in vivo implantation
The scaffolds with cells seeded for in vivo implantation
were prepared in a similar way as previously described
[6,24]. Briefly, scaffolds 12 mm in diameter and 1.5 mm
thickness were prewet with MesenCult complete medium
(StemCell Technologies) and incubated overnight at 37°C
and 5% CO2. Then, 5 × 10
5 cells were seeded per scaffold,
either MSCs alone or MSCs/ECs in a 5:1 ratio. To facili-
tate distribution of cells, an orbital shaker (Eppendorf,
Hamburg, Germany) was used, and cells were allowed to
attach overnight before scaffolds were transferred to separ-
ate modified spinner flasks (Wheaton Science, Millville,
NJ, USA) for 1 week in a dynamic culture system with 50
Table 1 List of TaqMan probes used for quantitative
real-time reverse transcription-polymerase chain
reaction analysis
Gene symbol Assay ID Lot number
GAPDH VIC MGB 4352339E
TNFα Mm 00443260_g1 1172346
IL1β Mm 00434228_m1 1172142
IL6 Mm 00446190_m1 1169749
IL4 Mm 00445259_m1 1173207
IL10 Mm 00439614_m1 1172560
iNOS Mm 00440502_m1 1171338
HIF1α Mm 00468869_m1 P121207-003A02
HIF1β (ARNT) Mm 00507836_m1 P110804-009B06
mTOR Mm 0044968_m1 P110708-007D02
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were punctured with a dermal skin puncher and the scaf-
folds were implanted in vivo.
Animal experiments
The animal experiments were performed after approval
from the Norwegian Animal Research Authority and con-
ducted according to the European Convention for the Pro-
tection of Vertebrates used for Scientific Purposes (local
approval number 3029). Non-obese diabetic/severe com-
bined immunodeficient (NOD/SCID) mice (n = 15) pur-
chased from Taconic Farms (Bomholtgård Breeding and
Research Center, Ry, Denmark) were used in this study.
The animals were kept in sterile polystyrene cages con-
taining wood shavings in a climate-controlled environ-
ment with 12 dark/light cycles and fed with standard
rodent chow and water ad libitum. The animals were 6 to
8 weeks at the time of the surgery. An intramuscular injec-
tion of 20 μL of Rompun (Xylazin) (20 mg/mL) (Bayer
Health Care, Leverkusen, Germany) and Narketan
(Ketamin) (Vétoquinol, Lure, France) in 1:2 ratios was
performed to anesthetize the animals. On the back of
the mice, a 2.5-cm incision was made providing suffi-
cient space for subcutaneous implantation of scaffolds.
A scaffold for each experimental group (MSC or MSC/
EC) was placed in the mouse, and six mice were used
for each time point. For the 3 weeks of implantation, an
additional six empty scaffolds were implanted in three
mice. Wounds were closed with Vetbond™ Tissue Adhe-
sive (n-butyl cyanoacrylate) (3M™, St. Paul, MN, USA).
After 1 or 3 weeks of implantation, animals were eutha-
nized with deep isoflurane (Schering Plough, Kenilworth,
NJ, USA) anesthesia followed by cervical dislocation, after
which the implanted scaffolds were carefully dissected and
retrieved. The samples were then cut into two halves, and
each half was further processed for real-time reverse
transcription-polymerase chain reaction (RT-PCR) ana-
lysis or histological embedding.
Real-time reverse transcription-polymerase chain reaction
RNA was extracted from the scaffolds by using an E.Z.
N.A. Total RNA Kit (Omega Bio-Tek, Norcross, GA,
USA) after being snap-frozen in liquid nitrogen. Quantifi-
cations and determination of RNA purity were performed
with a NanoDrop Spectrophotometer (ThermoScientific
NanoDrop Technologies, Wilmington, DE, USA). A high-
capacity cDNA Archive Kit (Applied Biosystems, Carlsbad,
CA, USA) was used for the reverse transcription reaction.
Total RNA (1,000 ng) was mixed with nuclease-free water,
reverse transcriptase buffer, random primers, deoxyribo-
nucleotide triphosphate (dNTP), and MultiScribe reverse
transcriptase. Standard enzyme and cycling conditions were
applied for 2 minutes at 50°C and 20 seconds at 95°C,
followed by 1 second at 95°C and 20 seconds at 60°C percycle (40 cycles). cDNA corresponding to 10 ng mRNA in
each reaction was prepared in duplicates since the standard
deviation between the duplicates was minimal for each
target gene. Real-time RT-PCR was performed on a
StepOnePlus™ real-time PCR system (Applied Biosys-
tems). Mouse-specific TaqMan gene expression assays
(Applied Biosystem) were used (Table 1). Data analysis
was performed with a comparative threshold cycle (Ct)
method with glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) as endogenous control [25].
Histological staining
The remaining part of the sample was immediately em-
bedded in optimal cutting temperature compound
(Tissue-Tek O.C.T., Sakura Finetek, Tokyo, Japan) and
kept at −80°C. Cryosectioning was done with Leica CM
3050S (Leica Microsystems, Wetzlar, Germany) at −24°C
with 8-μm-thick sections. Sections from the middle part
of the scaffolds were used for immunostaining. Samples
intended for paraffin sectioning were fixed in 4% parafor-
maldehyde. Sections from the middle part of the samples
were deparaffinized and stained with hematoxylin and
eosin. Sections obtained after 3 weeks of implantation
were incubated with primary antibodies in blocking buffer
overnight at 4°C and with secondary antibodies for 2 hours
the following morning. Nuclei were stained with 4′,6-dia-
midino-2-phenylindole (DAPI) (1:1,000) for 2 minutes,
and the slides were mounted with Prolong® Gold Antifade
Reagent (Invitrogen, Carlsbad, CA, USA) before imaging.
Exposure time and fluorescence intensities were normal-
ized to appropriate control images.
Rabbit polyclonal anti-mouse interleukin-1-beta (IL-1β)
antibody (Abcam, Cambridge, UK), rat monoclonal anti-
mouse neutrophil antibody (NIMP) (Abcam), rabbit
polyclonal anti-mouse IL-6 antibody (Abcam), and rat
monoclonal anti-mouse CD11b antibody (BD Biosciences,
San Jose, CA, USA) were used as primary antibodies.
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Biotechnology, Santa Cruz, CA, USA) and Alexa Fluor
546 goat anti-rat (Invitrogen) were used as secondary anti-
bodies. Double staining with IL-1β and NIMP antibodies
was performed to identify the number of IL-1β-positive
cells and the number of neutrophils, respectively. Double
staining with IL-6 and CD11b antibodies was performed
to co-localize macrophages or monocyte-derived cells and
their production of IL-6.
Quantification of immunostaining
On each slide, five sections from one scaffold were
mounted. Each section on the slides was divided onto
five measuring grids starting from top to bottom in ver-
tical direction. Five sections on each slide (average for
the mouse) and five measuring grids in each section
(average for the section) were used for the image quanti-
fication. The images were taken with Zeiss AxioVision
4.8.1 (Carl Zeiss, Toronto, ON, Canada) at magnification
of 10×, and the files were exported as JPEG standard.
The measuring grids in each section were noted care-
fully to avoid any overlap while taking the images. In
each section, the areas with no cells were excluded. NIS
elements AR 3.2 software (NIS elements, Tokyo, Japan)
was used for quantifications. First, the threshold was de-
fined for each channel: red, green, and blue. Next, all the
channels were simultaneously referred before counting the
cells to avoid misinterpretation. The blue channel was re-
ferred continuously to visualize the nuclei, and then the
counting was done in the red and green channels separ-
ately. Finally, co-localized cells were counted for red and
green fluorescent staining together. The number of
counted cells per measuring grid was exported to a Micro-
soft Excel (Microsoft Corporation, Redmond, WA, USA)
file before statistical analysis was performed.
Western blotting
Protein extraction was performed in accordance with
the protocol of Chomczynski [26]. Briefly, protein pre-
cipitation from the organic phase was prepared by add-
ing isopropanol. Precipitate was washed with ethanol
and dissolved in 0.5% sodium dodecyl sulfate solution.
Quantifications and determination of protein purity
were performed with a NanoDrop Spectrophotometer
(ThermoScientific NanoDrop Technologies). Total pro-
tein (30 μg) was mixed with 4X Laemmli sample buffer
(Bio-Rad Laboratories, Hercules, CA, USA) and loaded on
4% to 15% Mini-PROTEAN TGX™ Precast Gel (Bio-Rad
Laboratories) for electrophoresis. Transfer was done with
polyvinylidene fluoride (PVDF) transfer membranes
(TRANS-Blot® Turbo™ System, Bio-Rad Laboratories).
The membranes were blocked overnight at 4°C followed
by primary antibodies—rabbit polyclonal anti-mouse IL-
1β (Abcam), rabbit polyclonal anti-mouse IL-6 (Abcam),and rabbit polyclonal anti-mouse GAPDH (Santa Cruz Bio-
technology) in blocking buffer overnight at 4°C—and with
secondary antibody: horseradish peroxidase-conjugated
goat anti-rabbit IgG (Bio-Rad Laboratories) for 1 hour. Im-
munoblotting bands were visualized by Immun-Star™
WesternC™ Chemiluminescence Kits, and a Gel Doc™ EZ
System (Bio-Rad Laboratories) was used for imaging and
protein-band assay.
Microarray
A microarray study of the gene expression profiles of
MSCs co-cultured with ECs in vitro was previously con-
ducted by our research group and reported recently [12].
From this study, a microarray data set was obtained
and processed further. Data analysis was performed by
J-Express 2009 software (MolMine, Hafrsfjord, Norway)
[27]. The significance analysis of microarrays (SAM)
method was used. The data sets were submitted to the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID) [28] as separate sets of inflammatory
related genes, and pathways were determined by Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
mapping. The data are publically available at the National
Center for Biotechnology Information with Gene Expression
Omnibus accession number GSE63099.
Statistical analysis
The significance level was set to P value of less than 0.05
for all statistical analysis, with n = 6 for each group and
time point. SPSS Statistics 21 (IBM, Armonk, NY, USA)
was applied for statistical processing and analysis. Two
groups (MSC and MSC/EC) were compared with the in-
dependent samples t test, whereas a multiple comparison
one-way analysis of variance was performed to compare
three experimental groups (MSC, MSC/EC, and empty
scaffold).
Results
Gene ontology analysis
The DAVID pathway database [28] was used to explore
and view functionally related genes. Multiple genes in the
Toll-like receptor signaling pathway (Figure 1A) and the
leukocyte transendothelial migration pathway (Figure 1B)
had been influenced by the ECs. The over-represented
genes in the respective pathways are presented in Table 2.
Cell migration to the construct
Hematoxylin-and-eosin staining showed the overall rela-
tionship between implanted scaffold and the local cells.
One- and three-week samples reflected the recruitment
of inflammatory cells in relation to the scaffold and pro-
gression over time (Figure 2C). Quantification of DAPI
staining was done to show the difference in total cells
migrating into the construct during the experimental
Figure 1 Genes involved in the leukocyte transendothelial migration and Toll-like receptor signaling pathways. The over-represented
gene lists were submitted to the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [28], and 24 genes were involved in
the Toll-like receptor signaling pathway (A), whereas seven genes were involved in the leukocyte transendothelial migration pathway (B). Upregulated
genes are labeled with a red star, and downregulated genes are labeled with a black star.
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Table 2 Up- and downregulated genes from microarray gene ontology analysis comparing MSC (control) and MSC/EC (test)
PROBE_ID Gene symbol Fold change FDR[i] PROBE_ID Gene symbol Fold change FDR[i]
Downregulated Upregulated
ILMN_1791447 CXCL12/SDF-1 −5.075 0 ILMN_1686109 CCL23 3.983 0.597
ILMN_1699651 IL6 −4.942 0 ILMN_1740609 CCL15 3.701 0.828
ILMN_1676663 TNFRSF11B −5.002 0 ILMN_2313672 IL1RL1 9.2 0.224
ILMN_2175912 ITGB2 −2.561 0 ILMN_2184373 IL8 9.954 0
ILMN_1685009 ITGAM −1.001 77.022 ILMN_1775501 IL1B 1.081 65.3
ILMN_1671353 IL12A −1.534 10.383 ILMN_2242900 IL1RL1 5.534 0.587
ILMN_1671509 CCL3/ MIP-1α −1.005 73.358 ILMN_1689518 PECAM1 6.288 0
ILMN_1700353 TRAF6 −1.056 36.202 ILMN_1719236 CDH5 12.865 0
ILMN_1772387 TLR2 −1.024 62.406 ILMN_1801584 CXCR4 1.772 0.67
ILMN_1722981 TLR5 −1.112 11.32 ILMN_1731048 TLR1 1.035 55.07
ILMN_1654560 TLR6 −1.004 75.359 ILMN_2155708 TLR3 1.043 15.787
ILMN_1677827 TLR7 −1.038 33.053 ILMN_1706217 TLR4 1.243 13.508
ILMN_1679798 TLR9 −1.046 44.43 ILMN_1682251 TLR8 1.034 63.84
ILMN_2298366 TLR10 −1.045 57.183 ILMN_1724533 LY96/MD-2 1.006 76.228
ILMN_1740015 CD14 −1.292 11.398 ILMN_1738523 MYD88 1.086 15.187
ILMN_1765523 TOLLIP −1.078 27.851 ILMN_1651346 TICAM2/TRAM 1.027 70.63
ILMN_1776703 TIRAP −1.044 10.91 ILMN_2379130 IRAK1 1.138 4.854
ILMN_1724863 TICAM1 −1.069 18.947 ILMN_1692352 IRAK4 1.162 9.159
EC, endothelial cell; FDR[i], false discovery rate; MSC, multipotent stromal cell.
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compared with 1 week (Figure 2D and 2E) (P <0.001).
Three representative areas of 200 × 200 μm2 per picture,
five pictures per section, and five sections per mouse
were used for quantification.
Real-time reverse transcription-polymerase chain reaction
RT-PCR for mouse-specific genes was performed on
in vivo samples to evaluate the mRNA expression of se-
lected biomarkers important for recruitment of acute
and chronic inflammatory cells as well as genes differen-
tially expressed under hypoxic conditions. After 1 week
of implantation, most of the target genes evaluated
showed no significant differences between the experi-
mental groups. However, IL-1β was significantly down-
regulated in the MSC/EC group (P <0.001) (Figure 3).
After 3 weeks of implantation, significant upregulations of
pro-inflammatory biomarkers were found, compared with
scaffolds implanted without cells. The mRNA expression
of IL-1β and IL-6 was higher for the MSC group com-
pared with MSC/EC constructs (Figure 4). There was
similar expression of IL-10, an anti-inflammatory marker,
for all of the groups. However, the mRNA expression
of nitric oxide synthase 2 (NOS2) was significantly up-
regulated in both the MSC and the MSC/EC groups
compared with control scaffolds implanted withoutcells. Hypoxia-inducible factor 1 alpha (HIF-1α), HIF-
1β, and mammalian target of rapamycin (mTOR) ex-
pression was upregulated in both groups compared
with the control. There was also a significant upregula-
tion of these genes in the MSC/EC group compared
with the MSC group.
Immunofluorescent staining and Western blotting
To investigate the association between inflammatory cy-
tokines and migrating leukocytes, we used immunofluor-
escence double staining on samples retrieved after
3 weeks of implantation (Figure 5A). A remarkable over-
expression of neutrophil-positive staining (P <0.001) was
found in constructs implanted with vascular ECs. IL-1β-
positive cells were fewer in the co-culture group than in
the mono-culture group, although a statistical difference
could not be found (Figure 5B). On the other hand, IL-1β-
positive cells were significantly more in the MSC and the
MSC/EC groups compared with control scaffolds im-
planted without cells (P <0.001) (Figure 5B).
Double staining for IL-6 and CD11b was performed
as shown in Figure 5A. IL-6- and CD11b-positive cells
were systematically quantified (Figure 6B). There was a
significantly lower expression in the tissue-engineered
constructs that included ECs compared with mono-
culture group. CD11b-positive multinucleated giant
Figure 2 Implantation of tissue-engineered constructs and subsequent cell migration. Experimental design of the in vivo study is
presented in (A), and a macroscopic image of the scaffold used is shown in (B). Stained samples (hematoxylin and eosin) at 1 and 3 weeks
(C) are shown at 4×, 20×, and 60× magnification with scale bars of 200, 50, and 10 μm, respectively. Multinucleated giant cells on the scaffold
surface (S) can be seen at high magnification. (D) Quantification of cells migrated into the construct during the experimental period (***P <0.001,
n = 6). (E) Nuclei of migrated cells visualized with 4′,6-diamidino-2-phenylindole (DAPI) staining. EC, endothelial cell; MSC, multipotent stromal cell.
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the scaffolds, contributing to their degradation process
(Figure 6B). Giant cells co-stained with CD11b and IL-6
are shown in Figure 5C. IL-6- and CD11b-positive cells
were significantly more in the MSC and MSC/EC groupscompared with control scaffolds implanted without cells
(Figure 6B) (P <0.001). Western blotting also revealed that
the protein levels of IL-1β (Figure 5C) and IL-6 (Figure 6C)
were lower in the co-culture group compared with the
mono-culture group.
Figure 3 Real-time reverse transcription-polymerase chain reaction (RT-PCR) for mouse-specific genes after 1 week of implantation
in vivo. Relative gene expression of tumor necrosis factor alpha (TNFα) (A), interleukin-1-beta (IL-1β) (B), IL-6 (C), IL-10 (D), nitric oxide synthase 2
(NOS2) (E), mammalian target of rapamycin (mTOR) (F), hypoxia-inducible factor 1 alpha (HIF-1α) (G), and HIF-1β (H) comparing multipotent
stromal cell (MSC) and MSC/endothelial cell (MSC/EC) constructs. Data are presented as mean ± standard deviation (n = 6). *P <0.05; **P <0.01;
***P <0.001. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 4 Real-time reverse transcription-polymerase chain reaction (RT-PCR) for mouse-specific genes after 3 weeks of implantation
in vivo. Relative gene expression of tumor necrosis factor alpha (TNFα) (A), interleukin-1-beta (IL-1β) (B), IL-6 (C), IL-10 (D), nitric oxide synthase 2
(NOS2) (E), mammalian target of rapamycin (mTOR) (F), hypoxia-inducible factor 1 alpha (HIF-1α) (G), and HIF-1β (H) comparing empty scaffolds
with the multipotent stromal cell (MSC) and MSC/endothelial cell (MSC/EC) constructs. Data are presented as mean ± standard deviation (n = 6).
*P <0.05; **P <0.01; ***P <0.001. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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The aim of this study was to investigate the early inflam-
matory response to implantation of tissue-engineeredconstructs containing human cells, and we therefore se-
lected a moderately immunocompromised animal model.
A xenograft model with implantation of human MSCs
Figure 5 Transmigration of neutrophils and expression of interleukin-1-beta (IL-1β). (A) Representative fluorescent micrographs of
monoclonal anti-neutrophil antibody (NIMP) and IL-1β staining from the empty scaffold, multipotent stromal cell (MSC), and MSC/endothelial cell
(MSC/EC) constructs, using mouse-specific antibodies after 3 weeks of implantation in vivo (10× magnification, scale bar = 100 μm). (B) The number of
neutrophils was significantly higher in the MSC/EC group (***P <0.001, n = 6). The number of IL-1β-positive cells was lower in the MSC/EC group, but
this was not a statistically significant difference. Five sections from each mouse and five images for each section were used for the image quantification.
(C) Relative protein expression of IL-1β in MSC and MSC/EC constructs.
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are unable to perform VDJ recombination and subsequent
production of antibodies but produce monocyte-derived
cells and neutrophils, so that an early innate immune re-
sponse can be induced [29]. However, analysis of add-
itional inflammatory cells and cytokines associated with
the adaptive immune response is one of the limitations of
this study. Analysis of the inflammatory response therefore
focused on the aforementioned neutrophils and monocyte-
derived cells during the first 3 weeks after implantation,
and the emphasis was on the transmigrations of these cells,
which are events of central importance for creating a favor-
able microenvironment for tissue regeneration.
Tissue-engineered constructs with or without seeded
vascular ECs were evaluated for their effect on transmigra-
tion of acute and chronic inflammatory cells following
subcutaneous implantation. A two-dimensional culturemodel in vitro was performed to identify pathways for the
observed modulation of the inflammatory stimuli, via a
microarray gene ontology analysis.
At the site of inflammation, neutrophils are the first
line of defense and are later replaced by monocyte-
derived cells, T cells, and B cells. The number of neutro-
phils after 3 weeks of implantation was significantly
higher on the constructs co-seeded with MSCs and ECs
compared with constructs seeded with MSCs only. In
addition, a reduced number of CD11b-positive cells were
found for constructs comprising MSCs and ECs. The
CD11b-positive cells were observed in close proximity
to the surface of the scaffolds, and most cells were large
and multinucleated. Biomaterials in tissue engineering
are generally considered temporary structural support
and delivery devices for bioactive molecules or stem cells
or both. The rate of biomaterial degradation is an
Figure 6 Density of monocyte-derived cells and expression of interleukin-6 (IL-6). (A) Representative fluorescent micrographs from the
empty scaffold, multipotent stromal cell (MSC), and MSC/endothelial cell (MSC/EC) constructs, showing mouse-specific CD11b- and IL-6-positive
multinucleated cells after 3 weeks of implantation in vivo (10× magnification, scale bar = 100 μm). Five sections from each mouse and five images
for each section were used for the image quantification. (B) The number of cells positive for CD11b and IL-6 was lower in the MSC/EC group
(*P <0.05, n = 6). (C) Relative protein expression of IL-6 in MSC and MSC/EC constructs. (D) Giant-cell co-staining with CD11b and IL-6 at 63×
magnification. Scale bar = 20 μm. Overall larger giant cells were observed in the MSC/EC group. S, scaffold.
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new extracellular matrix proteins that are intended to
gradually replace the degrading material. The release of
degradation products influences the pH in the local en-
vironment, potentially prolonging inflammation and in-
fluencing tissue repair, and polymer degradation is in
part a result of a foreign-body giant-cell reaction [30].
Interestingly, the multinucleated giant cells in the MSC/
EC group were generally larger, whereas in the MSC
group an increased number of cells were observed, but
these were smaller cells with fewer nuclei. These obser-
vations were not quantified, and longer observation time
would be of further interest to evaluate whether the rate
of degradation was influenced by the altered morphology
of the multinucleated giant cells. Cross-sectional time
points also have limitations in describing the develop-
ment of acute and chronic inflammation but are useful
in observing phase shifts between experimental groups.Various cytokines are involved in attracting leukocytes
from the systemic circulation to the site of a tissue defect.
We performed analysis of gene expression on selected in-
flammatory biomarkers after 1 and 3 weeks of implant-
ation. In the comparison of the MSC and MSC/EC
groups, most target genes evaluated after 1 week were not
significantly different, except IL-1β, which was clearly
downregulated (P <0.001) in the MSC/EC group. This
downregulation was also found after 3 weeks (P <0.001),
and IL-1β expression was also strongly upregulated in the
MSC group compared with the empty control scaffolds
(P <0.001). Also, immunostaining and Western blotting
for IL-1β showed a downregulation in the MSC/EC group
after 3 weeks of implantation, but this was not statistically
significant. The expression of IL-1β was, however, in-
versely related to the number of transmigrated neutrophils
detected at the same time point, which was strongly
increased with the implantation of ECs. Additional time
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long-term effect of the release of IL-1β on neutrophil re-
cruitment to the constructs. However, reliable information
about the long-term immune response could not be ob-
tained with the animal model selected in this study.
Analysis of human-specific gene and protein expression
would also have been of interest to evaluate the inflamma-
tory stimuli delivered directly by the implanted cells.
Hematoxylin-and-eosin staining was used to study migra-
tion of murine cells into constructs, showing that the
scaffolds were not rejected by the host cells. Multiple in-
flammatory biomarkers were influenced on the mRNA
level after 3 weeks of implantation. IL-6 is a cytokine which
exhibits both pro- and anti-inflammatory properties, and
IL-6 trans-signaling helps to switch from neutrophils to
monocytes by activating different chemokines [31]. IL-6
produced by MSCs can inhibit T-cell proliferation [32],
and IL-6-dependent prostaglandin E2 (PGE2) secretion by
MSCs can modulate the immune response by reducing
the local inflammation [33]. In addition, MSCs can switch
immune profiles from Th1 to Th2 through production of
IL-6 [33].
The mRNA expression of IL-6 was significantly upregu-
lated in both the MSC and the MSC/EC groups compared
with the empty control scaffolds (P <0.001), and the ex-
pression in the MSC group was higher than in the MSC/
EC group (P <0.05). The results were confirmed with im-
munostaining for IL-6-positive cells and Western blotting.
Overall, the expression of pro-inflammatory cyto-
kines was reduced by adding ECs to the constructs.
However, the expression was still higher than in the
control group. Previous results have shown that im-
plantations of human cells in this experimental animal
model have generated an increased vascular density,
and this could be suggested as a consequence of the re-
lease of inflammatory cytokines [6].
Cytokines, chemokines, and growth factors are re-
leased from a site of injury, attracting native MSCs [34].
Immunomodulatory properties of MSCs are influenced by
local recruitment of inflammatory cells which secret pro-
inflammatory cytokines interferon-gamma, tumor necrosis
factor alpha (TNFα), IL-1α, and IL-1β. These cytokines in-
duce upregulations of inducible nitric oxide synthase
(NOS2) and chemokines, resulting in accumulation of T
cells, B cells, and other immune cells responding to im-
planted MSCs. Increased levels of nitrous oxide can also
suppress immune cell function [35,36], and the observed
upregulated expression of genes encoding NOS2 could
lead to upregulated expression of NOS2 and thus contrib-
ute to leukocyte recruitment and function.
Several target genes expressed during tissue hypoxia
were upregulated in both experimental groups compared
with the control, and the highest expression was de-
tected in the MSC/EC group.Tissue hypoxia is directly related to inflammation,
and inflamed resident and immune cells are highly
metabolic and their oxygen consumption is very high.
These cells migrate from a high oxygen tension in the
blood stream to a hypoxic environment, resulting in
production of HIFs. HIFs also exhibit both pro- and
anti-inflammatory properties [37,38] and regulate the
microenvironment at the site of inflammation. Cells
from the myeloid lineage are also regulated by HIFs,
and knockdown of HIF genes results in the impairment
of both acute and chronic inflammatory processes [38].
In the present work, upregulated expression of HIF
genes could be correlated to an increased acute inflam-
mation. Measurements of tissue oxygen tension would
be of interest to further explore these findings.
MSCs express various genes in the Toll-like receptor
pathway, recruiting cells to sites of injury by activating
both the innate and adaptive immune system. TLR4 and
TLR3 and their ligands have the capability to induce nu-
clear factor-κβ activity as well as the production of IL-6,
IL-8, and CXCL10 [39]. It has been postulated that MSCs
could also be attracted to a site by similar mechanisms.
MSCs express different Toll-like receptors which directly
affect the cell homing of other MSCs. TLR4-primed MSCs
regulate pro-inflammatory cytokines, whereas TLR3-
primed MSCs regulate anti-inflammatory cytokines. The
production of IL-6 and IL-8 is a downstream mechan-
ism of Toll-like receptors [40,41]. Our gene ontology
data detected a total of 24 over-represented genes in the
Toll-like receptor pathway after co-culture with ECs,
modulating the production of inflammatory cytokines,
and with both TLR3 and TLR4 upregulated in the MSC/
EC group. The pro-inflammatory cytokine IL-6 was
downregulated by fivefold, whereas IL-8—a cytokine
acting as both a potent chemoattractant and an inducer
of neutrophil activation—was upregulated by 10-fold in
the MSC/EC group [42]. The CXCL12/CXCR4 axis is a
key factor for homing neutrophils within the bone mar-
row and blood and has a major role in leukocyte traf-
ficking in both homeostasis and inflammation [43]. The
CXCL12/CXCR4 axis was downregulated in the MSC/
EC group, and the influence of ECs on Toll-like recep-
tor signaling and CXCL12/CXCR4 axis signaling pre-
sents possible pathways for activation of leukocyte
transendothelial migration.
Conclusions
The addition of vascular ECs to tissue-engineered con-
structs clearly influenced transmigration of leukocytes in-
volved in both acute and chronic inflammation. After
3 weeks of implantation, the number of neutrophils was
significantly increased, whereas the number of monocyte-
derived cells was decreased, suggesting a phase shift in the
inflammatory response with the presence of ECs.
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expression of inflammatory cytokines, and gene ontology
analysis revealed multiple genes in the leukocyte transmi-
gration and Toll-like receptor pathways regulated by ECs.
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